

Ewan R Pearson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2030137/publications.pdf>

Version: 2024-02-01

137
papers

10,948
citations

61857

43
h-index

33814

99
g-index

148
all docs

148
docs citations

148
times ranked

13177
citing authors

#	ARTICLE	IF	CITATIONS
1	The mechanisms of action of metformin. <i>Diabetologia</i> , 2017, 60, 1577-1585.	2.9	1,421
2	Activating Mutations in the Gene Encoding the ATP-Sensitive Potassium-Channel Subunit Kir6.2 and Permanent Neonatal Diabetes. <i>New England Journal of Medicine</i> , 2004, 350, 1838-1849.	13.9	1,077
3	Switching from Insulin to Oral Sulfonylureas in Patients with Diabetes Due to Kir6.2 Mutations. <i>New England Journal of Medicine</i> , 2006, 355, 467-477.	13.9	878
4	Genetic cause of hyperglycaemia and response to treatment in diabetes. <i>Lancet</i> , The, 2003, 362, 1275-1281.	6.3	526
5	Metformin and the gastrointestinal tract. <i>Diabetologia</i> , 2016, 59, 426-435.	2.9	472
6	Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. <i>Nature Genetics</i> , 2011, 43, 117-120.	9.4	390
7	Macrosomia and Hyperinsulinaemic Hypoglycaemia in Patients with Heterozygous Mutations in the HNF4A Gene. <i>PLoS Medicine</i> , 2007, 4, e118.	3.9	349
8	New loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolism. <i>Nature Genetics</i> , 2013, 45, 76-82.	9.4	293
9	Variation in <i>TCF7L2</i> Influences Therapeutic Response to Sulfonylureas. <i>Diabetes</i> , 2007, 56, 2178-2182.	0.3	284
10	Using machine learning approaches for multi-omics data analysis: A review. <i>Biotechnology Advances</i> , 2021, 49, 107739.	6.0	277
11	Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2020, 43, 1617-1635.	4.3	204
12	Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. <i>Diabetes</i> , 2015, 64, 1786-1793.	0.3	188
13	Relapsing diabetes can result from moderately activating mutations in <i>KCNJ11</i> . <i>Human Molecular Genetics</i> , 2005, 14, 925-934.	1.4	184
14	Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes. <i>Diabetes Care</i> , 2016, 39, 1879-1888.	4.3	172
15	Variation in the glucose transporter gene <i>SLC2A2</i> is associated with glycemic response to metformin. <i>Nature Genetics</i> , 2016, 48, 1055-1059.	9.4	165
16	Reduced-Function <i>SLC22A1</i> Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study. <i>Diabetes</i> , 2009, 58, 1434-1439.	0.3	153
17	Type 2 diabetes: a multifaceted disease. <i>Diabetologia</i> , 2019, 62, 1107-1112.	2.9	129
18	Genetic Evidence for a Link Between Favorable Adiposity and Lower Risk of Type 2 Diabetes, Hypertension, and Heart Disease. <i>Diabetes</i> , 2016, 65, 2448-2460.	0.3	122

#	ARTICLE	IF	CITATIONS
19	Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 637-646.	5.5	120
20	Contrasting Diabetes Phenotypes Associated With Hepatocyte Nuclear Factor-1 α and -1 β Mutations. <i>Diabetes Care</i> , 2004, 27, 1102-1107.	4.3	114
21	Novel subgroups of type 2 diabetes and their association with microvascular outcomes in an Asian Indian population: a data-driven cluster analysis: the INSPIRED study. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001506.	1.2	112
22	Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients. <i>Diabetes Care</i> , 2017, 40, 1017-1025.	4.3	111
23	Most People With Long-Duration Type 1 Diabetes in a Large Population-Based Study Are Insulin Microsecretors. <i>Diabetes Care</i> , 2015, 38, 323-328.	4.3	104
24	A Genome-Wide Association Study of IVGTT-Based Measures of First-Phase Insulin Secretion Refines the Underlying Physiology of Type 2 Diabetes Variants. <i>Diabetes</i> , 2017, 66, 2296-2309.	0.3	102
25	Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2020, 63, 1671-1693.	2.9	102
26	Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. <i>Diabetes Care</i> , 2020, 43, 1356-1359.	4.3	102
27	Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 481-487.	5.5	101
28	Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. <i>Diabetes Care</i> , 2018, 41, 1844-1853.	4.3	91
29	Visit-to-Visit HbA1c Variability Is Associated With Cardiovascular Disease and Microvascular Complications in Patients With Newly Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 426-432.	4.3	85
30	C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase. <i>Diabetes Care</i> , 2018, 41, 1486-1492.	4.3	81
31	Adherence to Oral Glucose-Lowering Therapies and Associations With 1-Year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database. <i>Diabetes Care</i> , 2016, 39, 258-263.	4.3	79
32	Genome-Wide and Abdominal MRI Data Provide Evidence That a Genetically Determined Favorable Adiposity Phenotype Is Characterized by Lower Ectopic Liver Fat and Lower Risk of Type 2 Diabetes, Heart Disease, and Hypertension. <i>Diabetes</i> , 2019, 68, 207-219.	0.3	72
33	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. <i>Diabetes Care</i> , 2018, 41, 705-712.	4.3	67
34	A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin. <i>Diabetologia</i> , 2018, 61, 2520-2527.	2.9	65
35	Monogenic Diabetes: From Genetic Insights to Population-Based Precision in Care. Reflections From a <i>Diabetes Care</i> Editors' Expert Forum. <i>Diabetes Care</i> , 2020, 43, 3117-3128.	4.3	65
36	Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1576-1584.	2.2	64

#	ARTICLE	IF	CITATIONS
37	Clinical and Genetic Determinants of Progression of Type 2 Diabetes: A DIRECT Study. <i>Diabetes Care</i> , 2014, 37, 718-724.	4.3	59
38	Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS). <i>International Journal of Epidemiology</i> , 2018, 47, 380-381j.	0.9	59
39	The Relationship between AKI and CKD in Patients with Type 2 Diabetes: An Observational Cohort Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 138-150.	3.0	56
40	Formalising recall by genotype as an efficient approach to detailed phenotyping and causal inference. <i>Nature Communications</i> , 2018, 9, 711.	5.8	54
41	<i>CYP2C8</i> and <i>SLCO1B1</i> Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 1902-1908.	4.3	52
42	Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. <i>Cardiovascular Diabetology</i> , 2016, 15, 97.	2.7	49
43	Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1579-1586.	2.2	49
44	Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18–50 years. <i>BMJ Open</i> , 2019, 9, e031586.	0.8	49
45	Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium. <i>Diabetologia</i> , 2014, 57, 1132-1142.	2.9	48
46	Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. <i>Nature Medicine</i> , 2022, 28, 982-988.	15.2	48
47	Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery. <i>Nature Reviews Endocrinology</i> , 2016, 12, 337-346.	4.3	47
48	Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 356-363.	2.2	47
49	Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register. <i>Diabetes Care</i> , 2018, 41, 2010-2018.	4.3	47
50	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts. <i>PLoS Medicine</i> , 2020, 17, e1003149.	3.9	47
51	Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , 2020, 43, 1948-1957.	4.3	45
52	Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study. <i>Diabetologia</i> , 2021, 64, 1982-1989.	2.9	44
53	Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by <i>SLC29A4</i>) and Organic Cation Transporter 1 (OCT1) (Encoded by <i>SLC22A1</i>) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study. <i>Diabetes Care</i> , 2019, 42, 1027-1033.	4.3	43
54	Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001238.	1.2	43

#	ARTICLE	IF	CITATIONS
55	Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study. <i>Diabetes Care</i> , 2016, 39, 1896-1901.	4.3	41
56	A common missense variant of LILRB5 is associated with statin intolerance and myalgia. <i>European Heart Journal</i> , 2017, 38, 3569-3575.	1.0	41
57	Quantifying the extent to which index event biases influence large genetic association studies. <i>Human Molecular Genetics</i> , 2017, 26, ddw433.	1.4	40
58	Rates of glycaemic deterioration in a real-world population with type 2 diabetes. <i>Diabetologia</i> , 2018, 61, 607-615.	2.9	40
59	Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study. <i>Cell Reports Medicine</i> , 2022, 3, 100477.	3.3	39
60	A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody-Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy. <i>Diabetes Care</i> , 2019, 42, 208-214.	4.3	35
61	Sharing data for future research'engaging participants' views about data governance beyond the original project: a DIRECT Study. <i>Genetics in Medicine</i> , 2019, 21, 1131-1138.	1.1	34
62	Genetic Variants in <i>CPA6</i> and <i>PRPF31</i> Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1428-1440.	0.3	32
63	Metabolite ratios as potential biomarkers for type 2 diabetes: a DIRECT study. <i>Diabetologia</i> , 2018, 61, 117-129.	2.9	32
64	Young-onset diabetes in Asian Indians is associated with lower measured and genetically determined beta cell function. <i>Diabetologia</i> , 2022, 65, 973-983.	2.9	32
65	Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank. <i>PLoS Medicine</i> , 2020, 17, e1003209.	3.9	31
66	Elevated circulating follistatin associates with an increased risk of type 2 diabetes. <i>Nature Communications</i> , 2021, 12, 6486.	5.8	31
67	Motivations for data sharing"views of research participants from four European countries: A DIRECT study. <i>European Journal of Human Genetics</i> , 2019, 27, 721-729.	1.4	30
68	Diabetes: Is There a Future for Pharmacogenomics Guided Treatment?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 329-337.	2.3	29
69	Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study. <i>Diabetes Care</i> , 2020, 43, 2493-2499.	4.3	29
70	Distinct Molecular Signatures of Clinical Clusters in People With Type 2 Diabetes: An IMI-RHAPSODY Study. <i>Diabetes</i> , 2021, 70, 2683-2693.	0.3	26
71	Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?. <i>PLoS ONE</i> , 2016, 11, e0152428.	1.1	26
72	Defining drug response for stratified medicine. <i>Drug Discovery Today</i> , 2017, 22, 173-179.	3.2	24

#	ARTICLE	IF	CITATIONS
73	Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 211-214.	2.2	24
74	Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration. <i>Journal of Hepatology</i> , 2019, 71, 594-602.	1.8	23
75	Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. <i>Diabetes Care</i> , 2021, 44, 2673-2682.	4.3	23
76	Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium. <i>Diabetologia</i> , 2019, 62, 1601-1615.	2.9	22
77	Metformin increases fasting glucose clearance and endogenous glucose production in non-diabetic individuals. <i>Diabetologia</i> , 2020, 63, 444-447.	2.9	22
78	A Polygenic Score for Type 2 Diabetes Risk Is Associated With Both the Acute and Sustained Response to Sulfonylureas. <i>Diabetes</i> , 2021, 70, 293-300.	0.3	22
79	No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 350-352.	2.2	20
80	Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes Genetic Risk Score Can Exclude Individuals With Type 1 Diabetes From Inappropriate Genetic Testing for Monogenic Diabetes. <i>Diabetes Care</i> , 2019, 42, e16-e17.	4.3	19
81	Zinc transport and diabetes risk. <i>Nature Genetics</i> , 2014, 46, 323-324.	9.4	18
82	Profiles of Glucose Metabolism in Different Prediabetes Phenotypes, Classified by Fasting Glycemia, 2-Hour OGTT, Glycated Hemoglobin, and 1-Hour OGTT: An IMI DIRECT Study. <i>Diabetes</i> , 2021, 70, 2092-2106.	0.3	17
83	Improvements in Awareness and Testing Have Led to a Threefold Increase Over 10 Years in the Identification of Monogenic Diabetes in the U.K.. <i>Diabetes Care</i> , 2022, 45, 642-649.	4.3	17
84	Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 4348.	3.0	16
85	Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study. <i>Diabetes Care</i> , 2021, 44, 511-518.	4.3	16
86	Association of Genetic Variant at Chromosome 12q23.1 With Neuropathic Pain Susceptibility. <i>JAMA Network Open</i> , 2021, 4, e2136560.	2.8	16
87	A roadmap to achieve pharmacological precision medicine in diabetes. <i>Diabetologia</i> , 2022, 65, 1830-1838.	2.9	16
88	Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach. <i>Clinical Epidemiology</i> , 2018, Volume 10, 1869-1877.	1.5	14
89	Predicting glycated hemoglobin levels in the non-diabetic general population: Development and validation of the DIRECT-DETECT prediction model - a DIRECT study. <i>PLoS ONE</i> , 2017, 12, e0171816.	1.1	13
90	The role of physical activity in metabolic homeostasis before and after the onset of type 2 diabetes: an IMI DIRECT study. <i>Diabetologia</i> , 2020, 63, 744-756.	2.9	12

#	ARTICLE	IF	CITATIONS
91	Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 761-771.	2.2	11
92	Prediction of Major Adverse Cardiovascular Events From Retinal, Clinical, and Genomic Data in Individuals With Type 2 Diabetes: A Population Cohort Study. <i>Diabetes Care</i> , 2022, 45, 710-716.	4.3	11
93	Statistical power considerations in genotype-based recall randomized controlled trials. <i>Scientific Reports</i> , 2016, 6, 37307.	1.6	10
94	What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study. <i>BMC Medicine</i> , 2019, 17, 79.	2.3	10
95	Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study. <i>Diabetes Therapy</i> , 2017, 8, 1031-1045.	1.2	9
96	The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2036-2046.	1.8	9
97	Integrative network analysis highlights biological processes underlying GLP-1 stimulated insulin secretion: A DIRECT study. <i>PLoS ONE</i> , 2018, 13, e0189886.	1.1	9
98	Dorothy Hodgkin Lecture 2021: Drugs, genes and diabetes. <i>Diabetic Medicine</i> , 2021, 38, e14726.	1.2	9
99	Pharmacogenetics and target identification in diabetes. <i>Current Opinion in Genetics and Development</i> , 2018, 50, 68-73.	1.5	8
100	Whole blood co-expression modules associate with metabolic traits and type 2 diabetes: an IMI-DIRECT study. <i>Genome Medicine</i> , 2020, 12, 109.	3.6	8
101	Strategies to identify individuals with monogenic diabetes: results of an economic evaluation. <i>BMJ Open</i> , 2020, 10, e034716.	0.8	8
102	Dissecting the Etiology of Type 2 Diabetes in the Pima Indian Population. <i>Diabetes</i> , 2015, 64, 3993-3995.	0.3	7
103	The governance structure for data access in the DIRECT consortium: an innovative medicines initiative (IMI) project. <i>Life Sciences, Society and Policy</i> , 2018, 14, 20.	3.1	7
104	Cohort profile: DOLORisk Dundee: a longitudinal study of chronic neuropathic pain. <i>BMJ Open</i> , 2021, 11, e042887.	0.8	7
105	Post-load glucose subgroups and associated metabolic traits in individuals with type 2 diabetes: An IMI-DIRECT study. <i>PLoS ONE</i> , 2020, 15, e0242360.	1.1	7
106	Quantitative MRI evaluation of whole abdomen adipose tissue volumes in healthy volunteers—validation of technique and implications for clinical studies. <i>British Journal of Radiology</i> , 2018, 91, 20180025.	1.0	6
107	Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype. <i>Journal of Personalized Medicine</i> , 2021, 11, 367.	1.1	6
108	CKMGlucose Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	5

#	ARTICLE	IF	CITATIONS
109	Genome-Wide Association Analysis of Pancreatic Beta-Cell Glucose Sensitivity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 80-90.	1.8	5
110	Utilizing Large Electronic Medical Record Data Sets to Identify Novel Drug-Gene Interactions for Commonly Used Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 816-825.	2.3	5
111	Evidence of a Causal Relationship between Serum Thyroid-Stimulating Hormone and Osteoporotic Bone Fractures. <i>European Thyroid Journal</i> , 2021, 10, 439-446.	1.2	5
112	Evidence-based prioritisation and enrichment of genes interacting with metformin in type 2 diabetes. <i>Diabetologia</i> , 2017, 60, 2231-2239.	2.9	4
113	Circulating Tissue Factor-Positive Procoagulant Microparticles in Patients with Type 1 Diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 12, 2819-2828.	1.1	4
114	Genetic Risk of Diverticular Disease Predicts Early Stoppage of Nicorandil. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1171-1175.	2.3	4
115	The impact of birthweight on subsequent phenotype of type 2 diabetes in later life. <i>Diabetic Medicine</i> , 2022, 39, e14792.	1.2	4
116	The search for predictive metabolic biomarkers for incident T2DM. <i>Nature Reviews Endocrinology</i> , 2018, 14, 444-446.	4.3	3
117	Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus – A MASTERMIND precision medicine approach (UKPDS 87). <i>Diabetes Research and Clinical Practice</i> , 2020, 166, 108333.	1.1	3
118	Dietary metabolite profiling brings new insight into the relationship between nutrition and metabolic risk: An IMI DIRECT study. <i>EBioMedicine</i> , 2020, 58, 102932.	2.7	3
119	The role of genetics in fetal programming of adult cardiometabolic disease. <i>Journal of Developmental Origins of Health and Disease</i> , 2022, 13, 292-299.	0.7	3
120	Prescribing Patterns and Response to Antihyperglycemic Agents Among Novel Clusters of Type 2 Diabetes in Asian Indians. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 190-200.	2.4	3
121	Reducing Glut2 throughout the body does not result in cognitive behaviour differences in aged male mice. <i>BMC Research Notes</i> , 2020, 13, 438.	0.6	2
122	Genomic editing of metformin efficacy-associated genetic variants in SLC47A1 does not alter SLC47A1 expression. <i>Human Molecular Genetics</i> , 2021, , .	1.4	2
123	4th ESPT Conference: pharmacogenomics and personalized medicine – research progress and clinical implementation. <i>Pharmacogenomics</i> , 2019, 20, 1063-1069.	0.6	1
124	In a cohort of individuals with type 2 diabetes using the drug sulfasalazine, HbA 1c lowering is associated with haematological changes. <i>Diabetic Medicine</i> , 2020, 38, e14463.	1.2	1
125	Polymorphism in INSR Locus Modifies Risk of Atrial Fibrillation in Patients on Thyroid Hormone Replacement Therapy. <i>Frontiers in Genetics</i> , 2021, 12, 652878.	1.1	1
126	Precision Medicine in Diabetes. <i>Handbook of Experimental Pharmacology</i> , 2022, , .	0.9	1

#	ARTICLE	IF	CITATIONS
127	PS7 - 3. Predicting Glycated Haemoglobin in the Non-Diabetic General Population: a DIRECT Study. Nederlands Tijdschrift Voor Diabetologie, 2013, 11, 154-154.	0.0	0
128	Crossover studies can help the individualisation of care in type 2 diabetes: the MASTERMIND approach. Practical Diabetes, 2016, 33, 115-117.	0.1	0
129	Response to Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948â€“1957. Diabetes Care, 2020, 43, e202-e203.	4.3	0
130	Genome-Wide Meta-Analysis Identifies the Organic Anion-Transporting Polypeptide Gene <i>SLCO1B1</i> and Statins as Modifiers of Glycemic Response to Sulfonylureas. SSRN Electronic Journal, 0, , .	0.4	0
131	The genetic association of the transcription factor NPAT with glycemic response to metformin involves regulation of fuel selection. PLoS ONE, 2021, 16, e0253533.	1.1	0
132	Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673â€“2682. Diabetes Care, 2022, 45, e82-e83.	4.3	0
133	Title is missing!. , 2020, 17, e1003149.		0
134	Title is missing!. , 2020, 17, e1003149.		0
135	Title is missing!. , 2020, 17, e1003149.		0
136	Title is missing!. , 2020, 17, e1003149.		0
137	Title is missing!. , 2020, 17, e1003149.		0